Colette N. Owens

Oncology
480 Red Hill Rd
Middletown, NJ 07748

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances
Published: February 24, 2026

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Journal: Cancers
Published: November 27, 2025

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Journal: Leukemia & lymphoma
Published: July 02, 2025

Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era.

Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era.

Journal: Blood cancer journal
Published: May 10, 2025

Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma.

Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma.

Journal: Haematologica
Published: March 11, 2025

Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma.

Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma.

Journal: British journal of haematology
Published: February 20, 2025

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

Journal: Blood advances
Published: February 10, 2025

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 11, 2024

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].

Journal: European urology
Published: October 19, 2024

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Journal: Haematologica
Published: August 01, 2024

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.

Journal: Blood
Published: June 18, 2024

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.

Journal: Haematologica
Published: April 15, 2024
Showing 1-12 of 30

Last Updated: 09/26/2026